Articolul precedent |
Articolul urmator |
359 5 |
Ultima descărcare din IBN: 2022-03-21 16:25 |
SM ISO690:2012 BOBESCU, Doina, CUSHNIR, V., LUPAN, Valentina, DUMBRĂVEANU, Lilia, GROPPA, Liliana, BOBESCU, Nicolae. Diagnosis and treatment of inflammatory glaucoma. Presentation of clinical cases. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 319. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 319-319 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Inflammatory (uveitic) glaucoma is a pathology in which eye inflammation causes persistent or periodic increase in IOP associated with anatomical and physiological changes specific to open-angle glaucoma. Objective of the study. To study the effect of anti-VEGF therapy (Bevacizumab) injected into the anterior chamber in patients with inflammatory glaucoma. Material and Methods. A clinical case study was performed in 9 patients - 14 eyes with refractory to treatment secondary anterior uveitis and rheumatoid arthritis, aged between 35 and 80 years, analyzed the effect of Bevacizumab injected into the anterior chamber. Patients were followed for a period of 1-9 years. Conventional treatment with corticosteroids, antibiotics, antifungals was also administered. Results. In 8 patients - 13 eyes was observed stabilization of IOP, improvement of inflammation and reduction of the complication rate. In 7 of them - 11 eyes, visual acuity varied within 1-2 rows, remission of the disease lasted 1-5 years. Macular edema persisted in one patient. Conclusion. 1. Bevacizumab has stabilized remission in patients with refractory to treatment uveitis for 1-5 years. 2. Bevacizumab improved the inflammatory process and decreased the rate of uveitis-specific complications, such as macular edema and neovascular glaucoma. |
||||||
Cuvinte-cheie inflammatory glaucoma, uveitis, Bevacizumab, glaucom inflamator, uveită, bevacizumab |
||||||
|